{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/itch-widespread/prescribing-information/chlorphenamine/","result":{"pageContext":{"chapter":{"id":"df24164a-a18e-5781-af2c-9d5424983d04","slug":"chlorphenamine","fullItemName":"Chlorphenamine","depth":2,"htmlHeader":"<!-- begin field 042af674-1e75-4bf7-a26c-3a798fb7cbc5 --><h2>Chlorphenamine</h2><!-- end field 042af674-1e75-4bf7-a26c-3a798fb7cbc5 -->","summary":"","htmlStringContent":"<!-- begin item 869a63f9-6318-45ee-b51f-18460829bf5a --><!-- end item 869a63f9-6318-45ee-b51f-18460829bf5a -->","topic":{"id":"98db983b-94d0-57fc-8f85-3c35dffdbc84","topicId":"3ff60e1b-3717-41cc-be12-1871b4284ba6","topicName":"Itch - widespread","slug":"itch-widespread","lastRevised":"Last revised in December 2016","chapters":[{"id":"c31a1ea7-3548-5767-9a55-10f56f4ea14a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"316853c8-d1ca-5613-8c4d-c33ea7c0fd8b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"64abf965-05aa-566d-999c-e216708a87b3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d34f3906-2823-5407-8f4d-32157480544d","slug":"changes","fullItemName":"Changes"},{"id":"8981751b-abe1-515d-b935-74b8a9b645f8","slug":"update","fullItemName":"Update"}]},{"id":"e1e55a0f-0001-592a-92fd-aacfa519336f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f8e85ce4-cb59-5950-9bb6-f4cc07f650a5","slug":"goals","fullItemName":"Goals"},{"id":"49927afa-5b0d-5fc5-9977-b9fbb4cb4db9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0cdcfdc7-2628-54da-8125-7d0470463e91","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9249d5b2-8df4-5432-adc8-2c07129d2033","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"60200ae0-6fe3-5aac-ba12-bfadcd7364eb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f57416b9-dc21-5b4f-b045-1a09f5148e92","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b96f535e-5376-53fa-b81c-21c88d0b344f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5e603eed-2553-5ec5-8250-3b6ff59aa984","slug":"definition","fullItemName":"Definition"},{"id":"5d85e75d-599f-583b-843d-861aeef9a901","slug":"causes","fullItemName":"Causes"},{"id":"ac8f2843-31dd-59dc-a6ea-cb91a03a2ff5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a022a03-81bf-5f1b-a367-0ecb842aa8b3","slug":"complications","fullItemName":"Complications"}]},{"id":"5520e3e5-dfa1-5437-aeef-2256ca61fbb4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1cf86197-a1ad-58fc-b46d-d2814ed58a17","slug":"history-examination","fullItemName":"History and examination"},{"id":"3b7bfad0-4337-523a-99e2-a2d249319c14","slug":"investigations","fullItemName":"Investigations"}]},{"id":"5da46787-c48f-5e2c-85d7-6a9a17e04771","fullItemName":"Management","slug":"management","subChapters":[{"id":"136349ec-02aa-57d6-97eb-349a8b186b91","slug":"management-of-widespread-itch","fullItemName":"Scenario: Management of widespread itch"}]},{"id":"a5778d5a-8940-58a1-82e1-4801b7a7ea9f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"df24164a-a18e-5781-af2c-9d5424983d04","slug":"chlorphenamine","fullItemName":"Chlorphenamine"},{"id":"d3b77011-f1f7-5074-ac46-2c0f5e15406a","slug":"hydroxyzine","fullItemName":"Hydroxyzine"}]},{"id":"3bc21e68-6ddb-5e67-9f24-6b13787b7d3c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2ebcf77c-c92c-5ef1-9321-590d2e905484","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bff96b70-ee2f-5eed-a1ab-c601465837a3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"76e9e0da-5a28-5e8f-a6a8-e08786d8da0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"838c111d-a9e4-5085-b44a-6f220b2e7f9a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8df3d2d7-e38f-5310-8b24-a8509771d9cd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74b7f8a8-8f89-5100-ad47-3f6c473ccaf7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f3e3af3a-d360-5e56-8053-6ff53dac1096","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a5778d5a-8940-58a1-82e1-4801b7a7ea9f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2cd98be5-1289-53a1-b7ff-dad082497cfc","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1847ddf6-3753-4ff0-8cf7-6aecfdfd963f --><h3>Contraindications and cautions</h3><!-- end field 1847ddf6-3753-4ff0-8cf7-6aecfdfd963f -->","summary":"","htmlStringContent":"<!-- begin item 436019ca-0df0-4e01-9ff5-f493e2323a1d --><!-- begin field c38b5eee-d7ab-4661-8e85-db576c67b1c3 --><ul><li><strong>Do not give chlorphenamine</strong> if the person has had a monoamine oxidase inhibitor (MAOI) within the last 2 weeks &mdash; the anticholinergic effects of chlorphenamine are intensified by MAOIs.</li><li><strong>Chlorphenamine should be used with caution in people with:</strong><ul><li>Hepatic impairment &mdash; avoid sedating antihistamines in severe liver disease.</li><li>Renal impairment.</li><li>Prostatic hypertrophy.</li><li>Urinary retention.</li></ul><ul><li>Severe hypertension or cardiovascular disease.</li><li>Raised intraocular pressure or glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Epilepsy &mdash; avoid antihistamines if possible, as they reduce the seizure threshold.</li><li>Asthma, bronchitis, or bronchiectasis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">BNF 70, 2015</a>]</p><!-- end field c38b5eee-d7ab-4661-8e85-db576c67b1c3 --><!-- end item 436019ca-0df0-4e01-9ff5-f493e2323a1d -->","subChapters":[]},{"id":"346a2bf7-b931-5a24-9659-59a21bfc6a2c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 74603bdc-9a31-484b-ab31-0316b3054354 --><h3>Adverse effects</h3><!-- end field 74603bdc-9a31-484b-ab31-0316b3054354 -->","summary":"","htmlStringContent":"<!-- begin item 5bad0f77-ac80-4ae9-ab41-5d7f199d6f3a --><!-- begin field ad07d20d-907a-4270-891d-7a5d224591ed --><ul><li><strong>Adverse effects of chlorphenamine include:</strong><ul><li>Neurological &mdash; dizziness, restlessness, psychomotor impairment, headaches, sedation.</li><li>Anticholinergic effects &mdash; blurred vision, dry mouth, and urinary retention.</li><li>Skin &mdash; urticaria, rash, exfoliative dermatitis, photosensitivity.</li><li>Gastrointestinal &mdash; nausea, vomiting, abdominal pain, diarrhoea, dyspepsia.</li><li>Cardiovascular &mdash; palpitations, tachycardia, arrhythmias.</li><li>Neuropsychiatric &mdash; depressed mood, excitation, irritability, nightmares, confusion.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">BNF 70, 2015</a>]</p><!-- end field ad07d20d-907a-4270-891d-7a5d224591ed --><!-- end item 5bad0f77-ac80-4ae9-ab41-5d7f199d6f3a -->","subChapters":[]},{"id":"18d16e0d-2d55-5d8f-b56e-a14f7800e22b","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f5a61f07-9e56-49f7-8e6a-6ba86950fd6e --><h3>Drug interactions</h3><!-- end field f5a61f07-9e56-49f7-8e6a-6ba86950fd6e -->","summary":"","htmlStringContent":"<!-- begin item 8eae451b-628f-491b-8f62-6b69adc52d10 --><!-- begin field 6305411e-bc06-4f69-b384-4226cc5505cd --><ul><li><strong>Possible drug interactions requiring caution include:</strong><ul><li>Hypnotics, anxiolytics, and opioids &mdash; may cause an increase in sedative effects.</li><li>Phenytoin &mdash; chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.<ul><li>If symptoms of toxicity are present (confusion, blurred vision, nystagmus, ataxia, or drowsiness), monitor serum phenytoin levels and reduce the dose if necessary.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/itch-widespread/references/\">BNF 70, 2015</a>]</p><!-- end field 6305411e-bc06-4f69-b384-4226cc5505cd --><!-- end item 8eae451b-628f-491b-8f62-6b69adc52d10 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}